Skip to main content
. 2012 Aug 14;120(12):2529–2536. doi: 10.1182/blood-2012-06-438911

Figure 3.

Figure 3

BAFF increases the cellular size of CD27− and CD27+ B cells from patients with cGVHD. (A) CD27− B cells or (B) CD27+ B cells incubated with BAFF for 24 or 48 hours and cell size analyzed by forward scatter (FSC). Left: Histograms represent (A) CD27− or (B) CD27+ B cells from a patient with cGVHD treated with BAFF for 24 hours (shaded area, thin line) and 48 hours (open area, bold line). Right: Median FSC quantified at 24 and 48 hours after BAFF treatment in (A) CD27− and (B) CD27+ B cells from patients with cGVHD. (A) Data are median ± range from a single experiment; n = 3. *P = .009 (unpaired 2-tailed t test). (B) Data are median ± range from a single experiment; n = 3. *P = .011 (unpaired 2-tailed t test).